Vertex Operating Cycle from 2010 to 2026

VRTX Stock  USD 463.86  5.82  1.24%   
Vertex Pharmaceuticals Operating Cycle yearly trend continues to be fairly stable with very little volatility. Operating Cycle is likely to outpace its year average in 2026. During the period from 2010 to 2026, Vertex Pharmaceuticals Operating Cycle regression line of annual values had r-squared of  0.09 and arithmetic mean of  221.55. View All Fundamentals
 
Operating Cycle  
First Reported
2010-12-31
Previous Quarter
306.7
Current Value
322.03
Quarterly Volatility
121.74600692
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Vertex Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vertex Pharmaceuticals' main balance sheet or income statement drivers, such as Total Revenue of 13.3 B, Gross Profit of 11.5 B or Other Operating Expenses of 13.6 B, as well as many indicators such as Price To Sales Ratio of 10.28, Dividend Yield of 0.0 or PTB Ratio of 7.62. Vertex financial statements analysis is a perfect complement when working with Vertex Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Vertex Stock
Check out the analysis of Vertex Pharmaceuticals Correlation against competitors.
For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.

Latest Vertex Pharmaceuticals' Operating Cycle Growth Pattern

Below is the plot of the Operating Cycle of Vertex Pharmaceuticals over the last few years. It is Vertex Pharmaceuticals' Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vertex Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Operating Cycle10 Years Trend
Slightly volatile
   Operating Cycle   
       Timeline  

Vertex Operating Cycle Regression Statistics

Arithmetic Mean221.55
Geometric Mean186.78
Coefficient Of Variation54.95
Mean Deviation84.49
Median204.98
Standard Deviation121.75
Sample Variance14,822
Range522
R-Value0.30
Mean Square Error14,407
R-Squared0.09
Significance0.25
Slope7.18
Total Sum of Squares237,153

Vertex Operating Cycle History

2026 322.03
2025 306.7
2024 340.77
2023 271.46
2022 214.57
2021 197.32
2020 191.26

About Vertex Pharmaceuticals Financial Statements

Vertex Pharmaceuticals investors use historical fundamental indicators, such as Vertex Pharmaceuticals' Operating Cycle, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Vertex Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Operating Cycle 306.70  322.03 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Vertex Stock Analysis

When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.